Oral vaccination: where we are?

Bibliography

• TADJBAKHSH H: In: History of Human and Veterinary Medicine in Iran. Fondation Merieux, Lyon (2003).
   Google Scholar
• SILIN DS, LIAO CW, LYUBOMSKA OV, WENG CN: Immunity development following oral vaccination against Actinobacillus pleuropneumoniae in a mouse model. Int. J. Biotechnol. (2007) (In Press).
   Google Scholar
• BOURINBAIAR AS, METADILOGKUL O, JIRATHITIKAL V: Mucosal AIDS vaccines. Viral Immunol. (2003) 16:427-445.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI I, KIYONO H: Gut as the largest immunologic tissue. J. Parenter. Enteral Nutr. (1999) 23(5 Suppl.):S7-S12.
   PubMed Web of Science ®Google Scholar
• PABST R, ROSENBERG YJ: Interpreting data on lymphocyte subsets in the blood of HIV patients – organ distribution, proliferation and migration kinetics are critical factors. Pathobiology (1998) 66(3-4):117-122.
   PubMed Web of Science ®Google Scholar
• HOLMGREN J, CZERKINSKY C, LYCKE N, SVENNERHOLM AM: Mucosal immunity: implications for vaccine development. Immunobiology (1992) 184(2-3):157-179.
   PubMed Web of Science ®Google Scholar
• MAYER L: Mucosal immunity and gastrointestinal antigen processing. J. Pediatr. Gastroenterol. Nutr. (2000) 30(Suppl.):S4-S12.
   PubMed Web of Science ®Google Scholar
• KERNEIS S, BOGDANOVA A, KRAEHENBUHL JP, PRINGAULT E: Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria. Science (1997) 277(5328):949-952.
   PubMed Web of Science ®Google Scholar
• BELLON G, OUNIS I: The preventive treatment of recurring respiratory infections using RU 41740 in 3,008 children. Ann. Pediatr. (Paris) (1990) 37(8):535-540.
   PubMedGoogle Scholar
• PAUPE J: Value of Imocur in the prevention of recurrent infections in children under six years of age. Results of a multicenter, placebo-controlled trial. Ann. Pediatr. (Paris) (1990) 37(7):475-479.
   PubMedGoogle Scholar
• RUTISHAUSER M, PITZKE P, GREVERS G et al.: Use of a polyvalent bacterial lysate in patients with recurrent respiratory tract infections: results of a prospective, placebo-controlled, randomized, double-blind study. Adv. Ther. (1998) 15(6):330-341.
   PubMed Web of Science ®Google Scholar
• SERRANO E, DEMANEZ JP, MORGON A, CHASTANG C, VAN CAUWENBERGE P: Effectiveness of ribosomal fractions of Klebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and the membrane fraction of Kp (Ribomunyl) in the prevention of clinical recurrences of infectious rhinitis. Results of a multicenter double-blind placebocontrolled study. Eur. Arch Otorhinolaryngol. (1997) 254(8):372-375.
   PubMed Web of Science ®Google Scholar
• TRACH DD, CLEMENS JD, KE NT et al.: Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet (1997) 349(9047):231-235.
   PubMed Web of Science ®Google Scholar
• HAMAJIMA K, SASAKI S, FUKUSHIMA J et al.: Intranasal administration of HIV-DNA vaccine formulated with a polymer, carboxymethylcellulose, augments mucosal antibody production and cell-mediated immune response. Clin. Immunol. Immunopathol. (1998) 88(2):205-210.
   PubMedGoogle Scholar
• MANNINO RJ, CANKI M, FEKETEOVA E et al.: Targeting immune response induction with cochleate and liposome-based vaccines. Adv. Drug Deliv. Rev. (1998) 32(3):273-287.
   PubMed Web of Science ®Google Scholar
• SAKAUE G, HIROI T, NAKAGAWA Y et al.: HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J. Immunol. (2003) 170(1):495-502.
   PubMed Web of Science ®Google Scholar
• SINGH M, VAJDY M, GARDNER J, BRIONES M, O'HAGAN D: Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity. Vaccine (2001) 20(3-4):594-602.
   PubMed Web of Science ®Google Scholar
• RYDELL N, STERTMAN L, STALENHEIM G, SJOHOLM I: Use of an oral diphtheria vaccine in human. Vaccine (2006) 24(33-34):5928-5930.
   PubMed Web of Science ®Google Scholar
• MITTAL SK, AGGARWAL N, SAILAJA G et al.: Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response. Vaccine (2000) 19(2-3):253-263.
   PubMed Web of Science ®Google Scholar
• RAJKANNAN R, DHANARAJU MD, GOPINATH D, SELVARAJ D, JAYAKUMAR R: Development of hepatitis B oral vaccine using B-cell epitope loaded PLG microparticles. Vaccine (2006) 24(24):5149-5157.
   PubMed Web of Science ®Google Scholar
• MOSER C, METCALF IC, VIRET JF: Virosomal adjuvanted antigen delivery systems. Expert Rev. Vaccine (2003) 2:189-196.
   PubMedGoogle Scholar
• CHALLACOMBE SJ, RAHMAN D, JEFFERY H, DAVIS SS, O'HAGAN DT: Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology (1992) 76(1):164-168.
   PubMed Web of Science ®Google Scholar
• KATZ DE, DELORIMIER AJ, WOLF MK et al.: Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine (2003) 21(5-6):341-346.
   PubMed Web of Science ®Google Scholar
• KANEKO H, BEDNAREK I, WIERZBICKI A et al.: Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology (2000) 267(1):8-16.
   PubMed Web of Science ®Google Scholar
• HERRMANN JE, CHEN SC, JONES DH et al.: Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles. Virology (1999) 259(1):148-153.
   PubMed Web of Science ®Google Scholar
• HUANG W, BAI Y, WANG JD et al.: Preparation oral liposome-encapsulated recombinant Helicobacter pylori heat shock protein 60 vaccine for prevention of Hp infection. Di Yi. Jun. Yi. Da. Xue. Xue. Bao. (2005) 25(5):531-534.
   PubMedGoogle Scholar
• TANA, WATARAI S, ISOGAI E, OGUMA K: Induction of intestinal IgA and IgG antibodies preventing adhesion of verotoxin-producing Escherichia coli to Caco-2 cells by oral immunization with liposomes. Lett. Appl. Microbiol. (2003) 36(3):135-139.
   PubMed Web of Science ®Google Scholar
• MIRCHAMSY H, MANHOURI H, HAMEDI M et al.: Stimulating role of toxoids-laden liposomes in oral immunization against diphtheria and tetanus infections. Biologicals (1996) 24(4):343-350.
   PubMed Web of Science ®Google Scholar
• KAZANJI M, LAURENT F, PERY P: Immune responses and protective effect in mice vaccinated orally with surface sporozoite protein of Eimeria falciformis in ISCOMs. Vaccine (1994) 12(9):798-804.
   PubMed Web of Science ®Google Scholar
• IOSEF C, VAN NGUYEN T, JEONG K et al.: Systemic and intestinal antibody secreting cell responses and protection in gnotobiotic pigs immunized orally with attenuated Wa human rotavirus and Wa 2/6-rotavirus-like-particles associated with immunostimulating complexes. Vaccine (2002) 20(13-14):1741-1753.
   PubMed Web of Science ®Google Scholar
• BABIUK S, BACA-ESTRADA ME, MIDDLETON DM et al.: Biphasic lipid vesicles (Biphasix) enhance the adjuvanticity of CpG oligonucleotides following systemic and mucosal administration. Curr. Drug Deliv. (2004) 1(1):9-15.
   PubMedGoogle Scholar
• FOSTER N, CLARK MA, JEPSON MA, HIRST BH: Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo. Vaccine (1998) 16(5):536-541.
   PubMed Web of Science ®Google Scholar
• SHARMA R, VAN DAMME EJ, PEUMANS WJ, SARSFIELD P, SCHUMACHER U: Lectin binding reveals divergent carbohydrate expression in human and mouse Peyer's patches. Histochem. Cell Biol. (1996) 105(6):459-465.
   PubMed Web of Science ®Google Scholar
• GIANNASCA PJ, GIANNASCA KT, LEICHTNER AM, NEUTRA MR: Human intestinal M cells display the sialyl Lewis A antigen. Infect. Immunol. (1999) 67(2):946-953.
   PubMed Web of Science ®Google Scholar
• KODAMA C, EGUCHI M, SEKIYA Y et al.: Evaluation of the Lon-deficient Salmonella strain as an oral vaccine candidate. Microbiol. Immunol. (2005) 4(12):1035-1045.
   Google Scholar
• WAHID R, SALERNO-GONCALVES R, TACKET CO, LEVINE MM, SZTEIN MB: Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909. Vaccine (2007) 25(8):1416-1425.
   PubMed Web of Science ®Google Scholar
• KIRKPATRICK BD, MCKENZIE R, O'NEILL JP et al.: Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine (2006) 2(2):116-123.
   Google Scholar
• HYLAND KA, BROWN DR, MURTAUGH MP: Salmonella enterica serovar Choleraesuis infection of the porcine jejunal Peyer's patch rapidly induces IL-1β and IL-8 expression. Vet. Immunol. Immunopathol. (2006) 109(1-2):1-11.
   PubMed Web of Science ®Google Scholar
• GANTOIS I, DUCATELLE R, TIMBERMONT L et al.: Oral immunisation of laying hens with the live vaccine strains of TAD Salmonella vac E and TAD Salmonella vac T reduces internal egg contamination with Salmonella Enteritidis. Vaccine (2006) 24(37-39):6250-6255.
   PubMed Web of Science ®Google Scholar
• WIGLEY P, HULME S, POWERS C et al.: Oral infection with the Salmonella enterica serovar Gallinarum 9R attenuated live vaccine as a model to characterise immunity to fowl typhoid in the chicken. BMC Vet. Res. (2005) 1:2.
   PubMedGoogle Scholar
• RAGOT C, GARNOTEL E, VEDY S, MORILLON M: Dukoral, oral cholera vaccine Dukoral, vaccin oral contre le cholera. Med. Trop. (Mars.) (2006) 6(3):237-239.
   Google Scholar
• ANH DD, CANH DG, LOPEZ AL et al.: Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine (2007) 25(6):1149-1155.
   PubMed Web of Science ®Google Scholar
• QADRI F, CHOWDHURY MI, FARUQUE SM et al.: Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine (2007) 25(2):231-238.
   PubMed Web of Science ®Google Scholar
• LIANG W, WANG S, YU F et al.: Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108. Infect. Immunol. (2003) 71(10):5498-5504.
   PubMed Web of Science ®Google Scholar
• QADRI F, AHMED T, AHMED F et al.: Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6 – 17 months of age: dosing studies in different age groups. Vaccine (2006) 24(10):1726-1733.
   PubMed Web of Science ®Google Scholar
• MAYR UB, HALLER C, HAIDINGER W et al.: Bacterial ghosts as an oral vaccine: a single dose of E. coli O157:H7 bacterial ghosts protects mice against lethal challenge. Infect. Immunol. (2005) 7(8):4810-4817.
   Google Scholar
• BOZIC F, LACKOVIC G, KOVSCA-JANJATOVIC A, SMOLEC O, VALPOTIC I: Levamisole synergizes experimental F4ac+ E. coli oral vaccine in stimulating ileal Peyer's patch T cells in weaned pigs. J. Vet. Pharmacol. Ther. (2006) 29(3):199-204.
   PubMed Web of Science ®Google Scholar
• HUSSAIN N, FLORENCE AT: Utilizing bacterial mechanisms of epithelial cell entry: invasininduced oral uptake of latex nanoparticles. Pharm. Res. (1998) 15:153-156.
   PubMed Web of Science ®Google Scholar
• BAUMLER AJ, TSOLIS RM, HEFFRON F: The lpf fimbrial operon mediates adhesion of Salmonella typhimurium to murine Peyer's patches. Proc. Natl. Acad. Sci. USA (1996) 93(1):279-283.
   PubMed Web of Science ®Google Scholar
• HAROKOPAKIS E, HAJISHENGALLIS G, MICHALEK SM: Effectiveness of liposomes possessing surface-linked recombinant B subunit of cholera toxin as an oral antigen delivery system. Infect. Immunol. (1998) 66(9):4299-4304.
   PubMed Web of Science ®Google Scholar
• LEE SH, MIZUTANI N, MIZUTANI M et al.: Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer. Cancer Immunol. Immunother. (2006) 55(12):1565-1574.
   PubMed Web of Science ®Google Scholar
• CHOU CK, HUNG JY, LIU JC , CHEN CT, HUNG MC: An attenuated Salmonella oral DNA vaccine prevents the growth of hepatocellular carcinoma and colon cancer that express alphafetoprotein. Cancer Gene Ther. (2006) 13(8):746-752.
   PubMed Web of Science ®Google Scholar
• MENG FP, DING J, YU ZC et al.: Oral attenuated Salmonella typhimurium vaccine against MG7-Ag mimotope of gastric cancer. World J. Gastroenterol. (2005) 11(12):1833-1836.
   PubMed Web of Science ®Google Scholar
• VRTALA S, GROTE M, FERREIRA F et al.: Humoral immune responses to recombinant tree pollen allergens (Bet v I and Bet v II) in mice: construction of a live oral allergy vaccine. Int. Arch. Allergy Immunol. (1995) 107(1-3):290-294.
   PubMed Web of Science ®Google Scholar
• CHEN Y, HELMUS R, MCCLANE B et al.: Use of a clostridium perfringens vector to express high levels of SIV p27 protein for the development of an oral SIV vaccine. Virology (2004) 329(2):226-233.
   PubMed Web of Science ®Google Scholar
• ZHAO X, ZHANG M, LI Z, FRANKEL FR: Vaginal protection and immunity after oral immunization of mice with a novel vaccine strain of Listeria monocytogenes expressing human immunodeficiency virus type 1 gag. J. Virol. (2006) 80(18):8880-8890.
   PubMed Web of Science ®Google Scholar
• NEESON P, BOYER J, KUMAR S et al.: A DNA prime-oral Listeria boost vaccine in rhesus macaques induces a SIV-specific CD8 T cell mucosal response characterized by high levels of α4β7 integrin and an effector memory phenotype. Virology (2006) 354(2):299-315.
   PubMed Web of Science ®Google Scholar
• RYAN ET, CREAN TI, JOHN M et al.: In vivo expression and immunoadjuvancy of a mutant of heat-labile enterotoxin of E. coli in vaccine and vector strains of Vibrio cholerae. Infect. Immunol. (1999) 67(4):1694-1701.
   PubMed Web of Science ®Google Scholar
• KOPROWSKI H, LEVINE MM, ANDERSON RJ et al.: Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic E. coli. Infect. Immunol. (2000) 68(9):4884-4892.
   PubMed Web of Science ®Google Scholar
• O'GAORA P, ROBERTS M, BOWE F et al.:Yersinia enterocolitica aroA mutants as carriers of the B subunit of the E. coli heat-labile enterotoxin to the murine immune system. Microb. Pathog. (1990) 9(2):105-116.
   PubMed Web of Science ®Google Scholar
• KAWAHARA M, HASHIMOTO A, TOIDA I, HONDA M: Oral recombinant Mycobacterium bovis bacillus Calmette-Guerin expressing HIV-1 antigens as a freeze-dried vaccine induces long-term, HIV-specific mucosal and systemic immunity. Clin. Immunol. (2002) 105(3):326-331.
   PubMed Web of Science ®Google Scholar
• KOTLOFF KL, WASSERMAN SS, JONES KF et al.: Clinical and microbiological responses of volunteers to combined intranasal and oral inoculation with a Streptococcus gordonii carrier strain intended for future use as a group A streptococcus vaccine. Infect. Immunol. (2005) 73(4):236-236.
   Google Scholar
• RAHA AR, VARMA NR, YUSOFF K, ROSS E, FOO HL: Cell surface display system for Lactococcus lactis: a novel development for oral vaccine. Appl. Microbiol. Biotechnol. (2005) 68(1):75-81.
   PubMed Web of Science ®Google Scholar
• WOLF JL, KAUFFMAN RS, FINBERG R et al.: Determinants of reovirus interaction with the intestinal M cells and absorptive cells of murine intestine. Gastroenterology (1983) 85(2):291-300.
   PubMed Web of Science ®Google Scholar
• RUBAS W, BANERJEA AC, GALLATI H, SPEISER PP, JOKLIK WK: Incorporation of the reovirus M cell attachment protein into small unilamellar vesicles: incorporation efficiency and binding capability to L929 cells in vitro. J. Microencapsul. (1990) 7(3):385-395.
   PubMed Web of Science ®Google Scholar
• HUTCHINGS AB, HELANDER A, SILVEY KJ et al.: Secretory immunoglobulin A antibodies against the sigma1 outer capsid protein of reovirus type 1 Lang prevent infection of mouse Peyer's patches. J. Virol. (2004) 78(2):947-957.
   PubMed Web of Science ®Google Scholar
• HELANDER A, SILVEY KJ, MANTIS NJ et al.: The viral sigma1 protein and glycoconjugates containing α2-3-linked sialic acid are involved in type 1 reovirus adherence to M cell apical surfaces. J. Virol. (2003) 77(14):7964-7977.
   PubMed Web of Science ®Google Scholar
• XIANG ZQ, GAO GP, REYES-SANDOVAL A et al.: Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J. Virol. (2003) 77(20):10780-10789.
   PubMed Web of Science ®Google Scholar
• HARA H, MONSONEGO A, YUASA K et al.: Development of a safe oral Aβ vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J. Alzheimers Dis. (2004) 6(5):483-488.
   PubMed Web of Science ®Google Scholar
• SCHECKELHOFF MR, TELFORD SR, HU LT: Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs. Vaccine (2006) 24(11):1949-1957.
   PubMed Web of Science ®Google Scholar
• ALLWRIGHT S, BRADLEY F, LONG J et al.: Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey. BMJ (2000) 321(7253):78-82.
   PubMed Web of Science ®Google Scholar
• WIMSATT J, BIGGINS D, INNES K, TAYLOR B, GARELL D: Evaluation of oral and subcutaneous delivery of an experimental canarypox recombinant canine distemper vaccine in the Siberian polecat (Mustela eversmanni). J. Zoo Wildl. Med. (2003) 34(1):25-35.
   PubMed Web of Science ®Google Scholar
• TAKAMURA S, NIIKURA M, LI TC et al.: DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration. Gene Ther. (2004) 11(7):628-635.
   PubMed Web of Science ®Google Scholar
• NIIKURA M, TAKAMURA S, KIM G et al.: Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes. Virology (2002) 293(2):273-280.
   PubMed Web of Science ®Google Scholar
• ZURBRIGGEN R, GLUCK R: Immunogenicity of IRIV- versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. Vaccine (1999) 17(11-12):1301-1305.
   PubMed Web of Science ®Google Scholar
• CUSI MG, DEL VECCHIO MT, TERROSI C et al.: Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine. J. Immunol. (2005) 174(11):7210-7216.
   PubMed Web of Science ®Google Scholar
• HUANG H, WU P, TEO C et al.: Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand. Int. J. Cancer (2004) 108(5):696-703.
   PubMed Web of Science ®Google Scholar
• LI Q, GAO JQ, QIU LY, CUI FD, JIN Y: Enhanced immune responses induced by vaccine using Sendai virosomes as carrier. Int. J. Pharm. (2007) 329(1-2):117-121.
   PubMed Web of Science ®Google Scholar
• KAPCZYNSKI DR: Development of a virosome vaccine against avian metapneumovirus subtype C for protection in turkeys. Avian Dis. (2004) 48(2):332-343.
   PubMed Web of Science ®Google Scholar
• SHOJI J, TANIHARA Y, UCHIYAMA T, KAWAI A: Preparation of virosomes coated with the vesicular stomatitis virus glycoprotein as efficient gene transfer vehicles for animal cells. Microbiol. Immunol. (2004) 48(3):163-174.
   PubMed Web of Science ®Google Scholar
• VRUBLEVSKAIA VV, VINOKUROV MG, KHOLODKOV OA, KORNEV AN, MORENKOV OS: Incorporation of glycoproteins of the Aujeszky's disease virus (Suid herpesvirus 1) into artificial liposome membranes and their interaction with cells. Vopr. Virusol. (2004) 49(2):32-36.
   PubMedGoogle Scholar
• HOMHUAN A, PRAKONGPAN S, POOMVISES P et al.: Virosome and ISCOM vaccines against Newcastle disease: preparation, characterization and immunogenicity. Eur. J. Pharm. Sci. (2004) 22(5):459-468.
   PubMed Web of Science ®Google Scholar
• ZURBRIGGEN R: Immunostimulating reconstituted influenza virosomes. Vaccine (2003) 21(9-10):921-924.
   PubMed Web of Science ®Google Scholar
• RIEDEMANN S, REINHARDT G, IBARRA H, FROSNER GG: Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in healthy toddlers and children in Chile. Acta Paediatr. (2004) 93(3):412-414.
   PubMed Web of Science ®Google Scholar
• MOSER C, METCALFE IC, VIRET JF: Virosomal adjuvanted antigen delivery systems . Expert Rev. Vaccines (2003) 2(2):189-196.
   PubMedGoogle Scholar
• LAMBKIN R, OXFORD JS, BOSSUYT S et al.: Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine. Vaccine (2004) 22(31-32):4390-4396.
   PubMed Web of Science ®Google Scholar
• CUSI MG, TERROSI C, SAVELLINI GG et al.: Efficient delivery of DNA to dendritic cells mediated by influenza virosomes. Vaccine (2004) 22(5-6):735-739.
   PubMed Web of Science ®Google Scholar
• CUSI MG, ZURBRIGGEN R, VALASSINA M et al.: Intranasal immunization with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity. Virology (2000) 277(1):111-118.
   PubMed Web of Science ®Google Scholar
• JAIN S, VYAS SP: Mannosylated niosomes as adjuvant-carrier system for oral mucosal immunization. J. Liposome Res. (2006) 16(4):331-345.
   PubMed Web of Science ®Google Scholar
• SINGH P, PRABAKARAN D, JAIN S et al.: Cholera toxin B subunit conjugated bile salt stabilized vesicles (bilosomes) for oral immunization. Int. J. Pharm. (2004) 278(2):379-390.
   PubMed Web of Science ®Google Scholar
• LELOUARD H, REGGIO H, MANGEAT P, NEUTRA M, MONTCOURRIER P: Mucinrelated epitopes distinguish M cells and enterocytes in rabbit appendix and Peyer's patches. Infect. Immunol. (1999) 67(1):357-367.
   PubMed Web of Science ®Google Scholar
• WELTZIN R, LUCIA-JANDRIS P, MICHETTI P et al.: Binding and transepithelial transport of immunoglobulins by intestinal M cells: demonstration using monoclonal IgA antibodies against enteric viral proteins. J. Cell Biol. (1989) 108(5):1673-1685.
   PubMed Web of Science ®Google Scholar
• VELEZ CN, TONKONOGY SL, LICHTMAN SN, CHO MJ: Sensitized liposomes as an antigen delivery system for the stimulation of mucosal immunity. J. Drug Target (1997) 5(1):15-24.
   PubMed Web of Science ®Google Scholar
• PAPPO J, ERMAK TH, STEGER HJ: Monoclonal antibody-directed targeting of fluorescent polystyrene microspheres to Peyer's patch M cells. Immunology (1991) 73(3):277-280.
   PubMed Web of Science ®Google Scholar
• STEPHENSON I, ZAMBON MC, RUDIN A et al.: Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic E. coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J. Virol. (2006) 80(10):4962-4970.
   PubMed Web of Science ®Google Scholar
• KENDE M, DEL GIUDICE G, RIVERA N, HEWETSON J: Enhancement of intranasal vaccination in mice with deglycosylated chain A ricin by LTR72, a novel mucosal adjuvant. Vaccine (2006) 24(12):2213-2221.
   PubMed Web of Science ®Google Scholar
• MELKEBEEK V, SONCK E, VERDONCK F, GODDEERIS BM, COX E: Optimized FaeG expression and a thermolabile enterotoxin DNA adjuvant enhance priming of an intestinal immune response by an FaeG DNA vaccine in pigs. Clin. Vaccine Immunol. (2007) 14(1):28-35.
   PubMed Web of Science ®Google Scholar
• KLEANTHOUS H, MYERS GA, GEORGAKOPOULOS KM et al.: Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect. Immunol. (1998) 66(6):2879-2886.
   PubMed Web of Science ®Google Scholar
• DUNN LA, MCMILLAN DJ, BATZLOFF M et al.: Parenteral and mucosal delivery of a novel multi-epitope M protein-based group A streptococcal vaccine construct: investigation of immunogenicity in mice. Vaccine (2002) 20(21-22):2635-2640.
   PubMed Web of Science ®Google Scholar
• SONG H, WANG Z, ZHENG D et al.: A novel mucosal vaccine against foot-and-mouth disease virus induces protection in mice and swine. Biotechnol. Lett. (2005) 27(21):1669-1674.
   PubMed Web of Science ®Google Scholar
• GONG ZH, JIN HQ, JIN YF, ZHANG YZ: Expression of cholera toxin B subunit and assembly as functional oligomers in silkworm. J. Biochem. Mol. Biol. (2005) 38(6):717-724.
   PubMedGoogle Scholar
• CONG H, GU QM, JIANG Y et al.: Oral immunization with a live recombinant attenuated Salmonella typhimurium protects mice against Toxoplasma gondii. Parasite Immunol. (2005) 27(1-2):29-35.
   PubMed Web of Science ®Google Scholar
• ANDERSEN CS, DIETRICH J, AGGER EM et al.: The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect. Immunol. (2007) 75(1):408-416.
   PubMed Web of Science ®Google Scholar
• GRDIC D, SMITH R, DONACHIE A et al.: The mucosal adjuvant effects of cholera toxin and immune-stimulating complexes differ in their requirement for IL-12, indicating different pathways of action. Eur. J. Immunol. (1999) 29(6):1774-1784.
   PubMed Web of Science ®Google Scholar
• ROSAS G, FRAGOSO G, AINCIART N et al.: Brucella spp. lumazine synthase: a novel adjuvant and antigen delivery system to effectively induce oral immunity. Microbes Infect. (2006) 8(5):1277-1286.
   PubMed Web of Science ®Google Scholar
• KAMINSKI RW, TURBYFILL KR, OAKS EV: Mucosal adjuvant properties of the Shigella invasin complex. Infect. Immunol. (2006) 74(5):2856-2866.
   PubMed Web of Science ®Google Scholar
• DUVERGER A, JACKSON RJ, VAN GINKEL FW et al.: Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens. J. Immunol. (2006) 176(3):1776-1783.
   PubMed Web of Science ®Google Scholar
• LEE SE, KIM SY, JEONG BC et al.: A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect. Immunol. (2006) 74(1):694-702.
   PubMed Web of Science ®Google Scholar
• VAN DE VERG LL, HARTMAN AB, BHATTACHARJEE AK et al.: Outer membrane protein of Neisseria meningitidis as a mucosal adjuvant for lipopolysaccharide of Brucella melitensis in mouse and guinea pig intranasal immunization models. Infect. Immunol. (1996) 64(12):5263-5268.
   PubMed Web of Science ®Google Scholar
• CHABOT S, BREWER A, LOWELL G et al.: A novel intranasal protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice. Vaccine (2005) 23(11):1374-1383.
   PubMed Web of Science ®Google Scholar
• BORSUTZKY S, EBENSEN T, LINK C et al.: Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. Vaccine (2006) 24(12):2049-2056.
   PubMed Web of Science ®Google Scholar
• OLIVE C, SCHULZE K, SUN HK et al.: Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation. Vaccine (2007) 25(10):1789-1797.
   PubMed Web of Science ®Google Scholar
• SLOAT BR, CUI Z: Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharm. Res. (2006) 23(6):1217-1226.
   PubMed Web of Science ®Google Scholar
• SLOAT BR, CUI Z: Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli. Vaccine (2006) 24(40-41):6405-6413.
   PubMed Web of Science ®Google Scholar
• TENGVALL S, LUNDQVIST A, EISENBERG RJ, COHEN GH, HARANDI AM: Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J. Virol. (2006) 80(11):5283-5291.
   PubMed Web of Science ®Google Scholar
• ZUERCHER AW, HORN MP, WU H et al.: Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa. Vaccine (2006) 24(20):4333-4342.
   PubMed Web of Science ®Google Scholar
• ABE N, KODAMA S, HIRANO T, ETO M, SUZUKI M: Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx. Laryngoscope (2006) 116(3):407-412.
   PubMed Web of Science ®Google Scholar
• KODAMA S, ABE N, HIRANO T, SUZUKI M: Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant. Laryngoscope (2006) 116(2):331-335.
   PubMed Web of Science ®Google Scholar
• MCCLUSKIE MJ, DAVIS HL: Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine (2000) 19(4-5):413-422.
   PubMed Web of Science ®Google Scholar
• ALDERSON MR, MCGOWAN P, BALDRIDGE JR, PROBST P: TLR4 agonists as immunomodulatory agents. J. Endotoxin Res. (2006) 12(5):313-319.
   PubMedGoogle Scholar
• BRACCI L, CANINI I, VENDITTI M et al.: Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus. Vaccine (2006) 24(Suppl. 2):S2-S7.
   PubMed Web of Science ®Google Scholar
• SABIROV A, METZGER DW: Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media. Vaccine (2006) 24(27-28):5584-5592.
   PubMed Web of Science ®Google Scholar
• MARINARO M, BOYAKA PN, FINKELMAN FD et al.: Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J. Exp. Med. (1997) 185(3):415-427.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON E, WESTRICH GM, VINEY JL: Modulating dendritic cells to optimize mucosal immunization protocols. J. Immunol. (1999) 163(7):3668-3675.
   PubMed Web of Science ®Google Scholar
• NOUR EL-DIN AN, SHKRETA L, TALBOT BG, DIARRA MS, LACASSE P: DNA immunization of dairy cows with the clumping factor A of Staphylococcus aureus. Vaccine (2006) 24(12):1997-2006.
   PubMed Web of Science ®Google Scholar
• SHAO W, LI X, LI M et al.: Macrophage inflammatory protein-1α expression plasmid enhances DNA vaccine-induced immune responses against HSV-2. Immunol. Cell Biol. (2005) 83(6):626-631.
   PubMed Web of Science ®Google Scholar
• LAVELLE EC, GRANT G, PUSZTAI A et al.: Mistletoe lectins enhance immune responses to intranasally co-administered herpes simplex virus glycoprotein D2. Immunology (2002) 107(2):268-274.
   PubMed Web of Science ®Google Scholar
• LAVELLE EC, GRANT G, PUSZTAI A, PFULLER U, O'HAGAN DT: The identification of plant lectins with mucosal adjuvant activity. Immunology (2001) 102(1):77-86.
   PubMed Web of Science ®Google Scholar
• BOYAKA PN, MARINARO M, JACKSON RJ et al.: Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity. J. Immunol. (2001) 166(4):2283-2290.
   PubMed Web of Science ®Google Scholar
• KERSTEN GFA, CROMMELIN DJA: Liposomes and ISCOMs. Vaccine (2003) 21(9-10):915-920.
   PubMed Web of Science ®Google Scholar
• ZHANG P, YANG QB, MARCIANI DJ et al.: Effectiveness of the quillaja saponin semisynthetic analog GPI-0100 in potentiating mucosal and systemic responses to recombinant HagB from Porphyromonas gingivalis. Vaccine (2003) 21(27-30):4459-4471.
   PubMed Web of Science ®Google Scholar
• ATKINSON HA, JOHNSON IT, GEE JM, GRIGORIADOU F, MILLER K: Brown Norway rat model of food allergy: effect of plant components on the development of oral sensitization. Food Chem. Toxicol. (1996) 34(1):27-32.
   PubMed Web of Science ®Google Scholar
• CHAVALI SR, BARTON LD, CAMPBELL JB: Immunopotentiation by orally-administered Quillaja saponins: effects in mice vaccinated intraperitoneally against rabies. Clin. Exp. Immunol. (1988) 74(3):339-343 .
   PubMed Web of Science ®Google Scholar
• ESTRADA A, LI B, LAARVELD B: Adjuvant action of Chenopodium quinoa saponins on the induction of antibody responses to intragastric and intranasal administered antigens in mice. Comp. Immunol. Microbiol. Infect. Dis. (1998) 21(3):225-236.
   PubMed Web of Science ®Google Scholar
• PICKERING RJ, SMITH SD, STRUGNELL RA, WESSELINGH SL, WEBSTER DE: Crude saponins improve the immune response to an oral plant-made measles vaccine. Vaccine (2006) 24(2):144-150.
   PubMed Web of Science ®Google Scholar
• NAGAI T, SUZUKI Y, KIYOHARA H et al.: Onjisaponins, from the root of Polygala tenuifolia Willdenow, as effective adjuvants for nasal influenza and diphtheria-pertussis-tetanus vaccines. Vaccine (2001) 19(32):4824-4834.
   PubMed Web of Science ®Google Scholar
• POPOV SV, GOLOVCHENKO VV, OVODOVA RG et al.: Characterisation of the oral adjuvant effect of lemnan, a pectic polysaccharide of Lemna minor L. Vaccine (2006) 24(26):5413-5419.
   PubMed Web of Science ®Google Scholar
• ISRAF DA, LAJIS NH, SOMCHIT MN, SULAIMAN MR: Enhancement of ovalbuminspecific IgA responses via oral boosting with antigen co-administered with an aqueous Solanum torvum extract. Life Sci. (2004) 75(4):397-406.
   PubMed Web of Science ®Google Scholar
• MEDINA-BOLIVAR F, WRIGHT R, FUNK V et al.: A non-toxic lectin for antigen delivery of plant-based mucosal vaccines. Vaccine (2003) 21(9-10):997-1005.
   PubMed Web of Science ®Google Scholar
• TRAIDL-HOFFMANN C, MARIANI V, HOCHREIN H et al.: Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization. J. Exp. Med. (2005) 201(4):627-636.
   PubMed Web of Science ®Google Scholar
• SCHENK R: Combination preparations of botanical extracts as adjuvants in oral mucosal defense. Zahnarztl. Prax. (1988) 39(8):290-297.
   PubMedGoogle Scholar
• ABDEL-SALAM OM, BAIUOMY AR, EL BATRAN S, ARBID MS: Evaluation of the anti-inflammatory, anti-nociceptive and gastric effects of Ginkgo biloba in the rat. Pharmacol. Res. (2004) 49(2):133-142.
   PubMed Web of Science ®Google Scholar
• MANABE M, TAKENAKA R, NAKASA T, OKINAKA O: Induction of anti-inflammatory responses by dietary Momordica charantia L. (bitter gourd). Biosci. Biotechnol. Biochem. (2003) 67(12):2512-2517.
   PubMed Web of Science ®Google Scholar
• KIM TG, GRUBER A, RUPRECHT RM, LANGRIDGE WH: Synthesis and assembly of SIVmac Gag p27 capsid protein cholera toxin B subunit fusion protein in transgenic potato. Mol. Biol. (2004) 28(1):33-40.
   Google Scholar
• NORDONE SK, PEACOCK JW, KIRWAN SM, STAATS HF: Capric acid and hydroxypropylmethylcellulose increase the immunogenicity of nasally administered peptide vaccines. AIDS Res. Hum. Retroviruses (2006) 22(6):558-568.
   PubMed Web of Science ®Google Scholar
• JOSEPH A, ITSKOVITZ-COOPER N, SAMIRA S et al.: A new intranasal influenza vaccine based on a novel polycationic lipid – ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Vaccine (2006) 24(18):3990-4006.
   PubMed Web of Science ®Google Scholar
• IVANOV AP, DRAGUNSKY EM, CHUMAKOV KM: 1,25-Dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice. J. Infect. Dis. (2006) 193(4):598-600.
   PubMed Web of Science ®Google Scholar
• BERGMANN KC, WALDMAN RH: Enhanced murine respiratory tract IgA antibody response to oral influenza vaccine when combined with a lipoidal amine (avridine). Int. Arch. Allergy Appl. Immunol. (1988) 87(3):334-335.
   PubMedGoogle Scholar
• PENG XM, XIE DY, GU L et al.: Effect of exogenous epitopes of helper T lymphocyte on humoral immunity of HBV S gene DNA immunity. Zhonghua Yi. Xue. Za Zhi. (2003) 83(3):232-236.
   PubMedGoogle Scholar
• ROSA DS, IWAI LK, TZELEPIS F et al.: Immunogenicity of a recombinant protein containing the Plasmodium vivax vaccine candidate MSP1(19) and two human CD4+ T-cell epitopes administered to non-human primates (Callithrix jacchus jacchus). Microbes Infect. (2006) 8(8):2130-2137.
   PubMed Web of Science ®Google Scholar
• NEUMANN F, WAGNER C, KUBUSCHOK B et al.: Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes. Cancer Immunol. Immunother. (2004) 53(7):589-599.
   PubMed Web of Science ®Google Scholar
• ALEXANDER J, DEL GUERCIO MF, MAEWAL A et al.: Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J. Immunol. (2000) 164(3):1625-1633.
   PubMed Web of Science ®Google Scholar
• ALEXANDER J, SIDNEY J, SOUTHWOOD S et al.: Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity (1994) 1(9):751-761.
   PubMed Web of Science ®Google Scholar
• RESSING ME, VAN DRIEL WJ, BRANDT RM et al.: Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J. Immunother. (2000) 23(2):255-266.
   PubMed Web of Science ®Google Scholar
• DAFTARIAN P, ALI S, SHARAN R et al.: Immunization with Th-CTL fusion peptide and cytosine-phosphate-guanine DNA in transgenic HLA-A2 mice induces recognition of HIV-infected T cells and clears vaccinia virus challenge. J. Immunol. (2003) 171(8):4028-4039.
   PubMed Web of Science ®Google Scholar
• DECROIX N, QUAN CP, PAMONSINLAPATHAM P, BOUVET JP: Mucosal immunity induced by intramuscular administration of free peptides in-line with PADRE: IgA antibodies to the ELDKWA epitope of HIV gp41. Scand. J. Immunol. (2002) 56(1):59-65.
   PubMed Web of Science ®Google Scholar
• PAMONSINLAPATHAM P, DECROIX N, MIHAILA-AMROUCHE L, BOUVET A, BOUVET JP: Induction of a mucosal immune response to the streptococcal M protein by intramuscular administration of a PADRE-ASREAK peptide. Scand. J. Immunol. (2004) 59(5):504-510.
   PubMed Web of Science ®Google Scholar
• ZHAO P, ZHAO LJ, CAO J, HONG HY, QI ZT: Enhancement of immune responses of hepatitis B virus core DNA vaccine by a signal Peptide and a universal helper T lymphocyte epitope. Sheng Wu Hua Xue. Yu Sheng Wu Wu Li Xue. Bao. (Shanghai) (2002) 34(3):341-346.
   PubMedGoogle Scholar
• GUO CC, DING J, PAN BR et al.: Development of an oral DNA vaccine against MG7-Ag of gastric cancer using attenuated salmonella typhimurium as carrier. World J. Gastroenterol. (2003) 9(6):1191-1195.
   PubMed Web of Science ®Google Scholar
• UYTTENHOVE C, ARENDSE B, STROOBANT V, BROMBACHER F, VAN SNICK J: Development of an anti-IL-12 p40 auto-vaccine: protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection. Eur. J. Immunol. (2004) 34(12):3572-3581.
   PubMed Web of Science ®Google Scholar
• MORAVEC T, SCHMIDT MA, HERMAN EM, WOODFORD-THOMAS T: Production of E. coli heat labile toxin (LT) B subunit in soybean seed and analysis of its immunogenicity as an oral vaccine. Vaccine (2007) 25(9):1647-1657.
   PubMed Web of Science ®Google Scholar
• MASON HS, HAQ TA, CLEMENTS JD, ARNTZEN CJ: Edible vaccine protects mice against E. coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine (1998) 16(13):1336-1343.
   PubMed Web of Science ®Google Scholar
• WEN SX, TEEL LD, JUDGE NA, O'BRIEN AD: A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2. Proc. Natl. Acad. Sci. USA (2006) 103(18):7082-7087.
   PubMed Web of Science ®Google Scholar
• LEE KY, KIM DH, KANG TJ et al.: Induction of protective immune responses against the challenge of Actinobacillus pleuropneumoniae by the oral administration of transgenic tobacco plant expressing ApxIIA toxin from the bacteria. FEMS Immunol. Med. Microbiol. (2006) 48(3):381-389.
   PubMed Web of Science ®Google Scholar
• WEBSTER DE, COONEY ML, HUANG Z et al.: Successful boosting of a DNA measles immunization with an oral plant-derived measles virus vaccine. J. Virol. (2002) 76:7910-7912.
   PubMed Web of Science ®Google Scholar
• RIGANO MM, DREITZ S, KIPNIS AP, IZZO AA, WALMSLEY AM: Oral immunogenicity of a plant-made, subunit, tuberculosis vaccine. Vaccine (2006) 24:691-695.
   PubMed Web of Science ®Google Scholar
• LAMPHEAR BJ, JILKA JM, KESL L et al.: A corn-based delivery system for animal vaccines: an oral transmissible gastroenteritis virus vaccine boosts lactogenic immunity in swine. Vaccine (2004) 22(19):2420-2424.
   PubMed Web of Science ®Google Scholar
• SHCHELKUNOV SN, SALYAEV RK, POZDNYAKOV SG et al.: Immunogenicity of a novel, bivalent, plant-based oral vaccine against hepatitis B and human immunodeficiency viruses. Biotechnol. Lett. (2006) 28(13):959-967.
   PubMed Web of Science ®Google Scholar
• SASAGAWA T, TANI M, BASHA W et al.: A human papillomavirus type 16 vaccine by oral delivery of L1 protein. Virus Res. (2005) 110(1-2):81-90.
   PubMed Web of Science ®Google Scholar
• JHA RK, XU ZR, BAI SJ et al.: Protection of Procambarus clarkii against white spot syndrome virus using recombinant oral vaccine expressed in Pichia pastoris. Fish Shellfish Immunol. (2007) 2(4):295-307.
   Google Scholar
• TAMARU Y, OHTSUKA M, KATO K et al.: Application of the arming system for the expression of the 380R antigen from red sea bream iridovirus (RSIV) on the surface of yeast cells: a first step for the development of an oral vaccine. Biol. Prog. (2006) 22(4):949-953.
   PubMedGoogle Scholar
• GONG Z, JIN Y, ZHANG Y: Suppression of diabetes in non-obese diabetic (NOD) mice by oral administration of a cholera toxin B subunit-insulin B chain fusion protein vaccine produced in silkworm. Vaccine (2007) 25(8):1444-1451.
   PubMed Web of Science ®Google Scholar
• SISKIND GW, HOWARD JG: Studies on the induction of immunological unresponsiveness to pneumococcal polysaccharide in mice. J. Exp. Med. (1966) 124(3):417-429.
   PubMed Web of Science ®Google Scholar
• KAGNOFF MF: Oral tolerance. Ann. NY Acad. Sci. (1982) 392:248-265.
   PubMed Web of Science ®Google Scholar
• TACKET CO, MASON HS: A review of oral vaccination with transgenic vegetables. Microbes Infect. (1999) 1(10):777-783.
   PubMed Web of Science ®Google Scholar
• SILIN DS, LYUBOMSKA OV: Overcoming immune tolerance during oral vaccination against actinobacillus pleuropneumoniae. J. Vet. Med. B (2002) 49:169-175.
   PubMedGoogle Scholar
• FOSTER N, HIRST BH: Exploiting receptor biology for oral vaccination with biodegradable particulates. Adv. Drug Deliv. Rev. (2005) 57(3):431-450.
   PubMed Web of Science ®Google Scholar
• STEINMAN RM, HAWIGER D, LIU K et al.: Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann. NY Acad. Sci. (2003) 987:15-25.
   PubMed Web of Science ®Google Scholar
• TAKAGI H, HIROI T, YANG L et al.: A rice-based edible vaccine expressing multiple T cell epitopes induces oral tolerance for inhibition of Th2-mediated IgE responses. Proc. Natl. Acad. Sci. USA (2005) 10(48):17525-17530.
   Google Scholar
• SAIF LJ: Coronavirus immunogens. Vet. Microbiol. (1993) 37(3-4):285-297.
   PubMed Web of Science ®Google Scholar
• SILIN DS, LYUBOMSKA OV, WENG CN: Mycoplasma hyopneumoniae vaccination influence on porcine reproductive and respiratory syndrome virus and mycoplasma hyopneumoniae coinfection. Acta Veterinaria Brn. (2001) 70:413-420.
   Web of Science ®Google Scholar
• BOURINBAIAR AS, JIRATHITIKAL V, METADILOGKUL O et al.: Phase II placebo-controlled study of V-1 Immunitor as a therapeutic modality for treatment of HIV. J. Clin. Virol. (2004) 31:S55-S62.
   PubMed Web of Science ®Google Scholar
• JIRATHITIKAL V, SOOKSATHAN P, METADILOGKUL O, BOURINBAIAR AS: V-1 Immunitor: oral therapeutic AIDS vaccine with prophylactic potential. Vaccine. (2003) 21:624-628.
   PubMed Web of Science ®Google Scholar